The stock of Xeris Biopharma Holdings Inc (NASDAQ: XERS) has increased by 1.04 when compared to last closing price of 4.31.Despite this, the company has seen a gain of 8.33% in its stock price over the last five trading days. businesswire.com reported 2025-03-28 that CHICAGO–(BUSINESS WIRE)–Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced changes to its board of directors. Ricki Fairley has resigned from the board in light of other commitments, effective immediately. The Board of Directors has appointed James Brady as a new director of Xeris’ board to fill the vacancy. In addition.
Is It Worth Investing in Xeris Biopharma Holdings Inc (NASDAQ: XERS) Right Now?
The 36-month beta value for XERS is at 0.94. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for XERS is 141.94M, and currently, shorts hold a 13.42% of that float. The average trading volume for XERS on April 28, 2025 was 2.99M shares.
XERS’s Market Performance
XERS’s stock has seen a 8.33% increase for the week, with a -22.65% drop in the past month and a 25.50% gain in the past quarter. The volatility ratio for the week is 5.50%, and the volatility levels for the past 30 days are at 7.34% for Xeris Biopharma Holdings Inc The simple moving average for the past 20 days is -0.93% for XERS’s stock, with a 28.09% simple moving average for the past 200 days.
Analysts’ Opinion of XERS
Many brokerage firms have already submitted their reports for XERS stocks, with Piper Sandler repeating the rating for XERS by listing it as a “Neutral.” The predicted price for XERS in the upcoming period, according to Piper Sandler is $3 based on the research report published on November 11, 2024 of the previous year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see XERS reach a price target of $5. The rating they have provided for XERS stocks is “Outperform” according to the report published on March 28th, 2024.
Craig Hallum gave a rating of “Buy” to XERS, setting the target price at $4.50 in the report published on August 28th of the previous year.
XERS Trading at -2.80% from the 50-Day Moving Average
After a stumble in the market that brought XERS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.25% of loss for the given period.
Volatility was left at 7.34%, however, over the last 30 days, the volatility rate increased by 5.50%, as shares sank -21.42% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +21.81% upper at present.
During the last 5 trading sessions, XERS rose by +9.08%, which changed the moving average for the period of 200-days by +103.48% in comparison to the 20-day moving average, which settled at $4.40. In addition, Xeris Biopharma Holdings Inc saw 28.47% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at XERS starting from Hecht Beth, who sale 40,000 shares at the price of $5.43 back on Mar 20 ’25. After this action, Hecht Beth now owns 1,353,510 shares of Xeris Biopharma Holdings Inc, valued at $217,244 using the latest closing price.
Hecht Beth, the Officer of Xeris Biopharma Holdings Inc, proposed sale 40,000 shares at $5.14 during a trade that took place back on Mar 20 ’25, which means that Hecht Beth is holding shares at $205,600 based on the most recent closing price.
Stock Fundamentals for XERS
Current profitability levels for the company are sitting at:
- -0.17 for the present operating margin
- 0.79 for the gross margin
The net margin for Xeris Biopharma Holdings Inc stands at -0.27. The total capital return value is set at -0.15. Equity return is now at value -617.16, with -16.37 for asset returns.
Based on Xeris Biopharma Holdings Inc (XERS), the company’s capital structure generated 2.19 points at debt to capital in total, while cash flow to debt ratio is standing at -0.68. The debt to equity ratio resting at -1.84. The interest coverage ratio of the stock is -1.1.
Currently, EBITDA for the company is -13.99 million with net debt to EBITDA at 1.23. When we switch over and look at the enterprise to sales, we see a ratio of 3.19. The receivables turnover for the company is 5.02for trailing twelve months and the total asset turnover is 0.63. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.67.
Conclusion
In conclusion, Xeris Biopharma Holdings Inc (XERS) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
